An increasing number of patients with parotid gland tumors have been observed in recent years. The relationship between the immune system and tumor formation is thoroughly investigated. However, newly discovered molecules offer a new insight into the pathophysiology of malignancies. It would be ideal to find an easily determinable biomarker of tumor existence, its malignant potential or a biomarker suggesting the probability of disease recurrence. Our study is the first to examine serum concentrations of IL-33 and its sST2 receptor in patients with various types of parotid gland tumors. Serum IL33, sST2, IL-4 and IL-10 concentrations were determined in patients with benign and malignant parotid gland tumors (pleomorphic adenoma, Warthin’s tumor, myoepithelioma and acinic cell carcinoma). We observed for the first time that serum IL-33 level was significantly elevated in patients with various types of parotid gland tumors and sST2 levels were significantly higher in pleomorphic adenoma and acinic cell carcinoma patients compared to the controls. Our results demonstrate for the first time that serum IL-33 and its sST2 receptor may be important factors in the pathology of parotid gland tumors. Although our results are promising, further investigations are required to detect if serum concentrations of those molecules may be a biomarker in parotid gland tumors.
Impact statement
Parotid gland tumors seem to be an increasingly important medical challenge, mostly due to a noticeable increase in the incidence. It would be crucial to find an easily determinable biomarker of tumor existence, its recurrence or malignant potential. We observed for the first time that serum IL-33 level was significantly elevated in patients with various types of parotid gland tumors and its sST2 receptor levels were significantly higher in pleomorphic adenoma and acinic cell carcinoma patients compared to the controls. We believe that our study helps to understand the biology of the tumors and a potential role of a relatively newly identified cytokine IL-33 in the pathophysiology of the parotid gland tumors.
FranzenABuchaliALiederA.The rising incidence of parotid metastases: our experience from four decades of parotid gland surgery. Acta Otorhinolaryngol Ital2017;
37:264–9
2.
XieSWangKXuHHuaRXLiTZShanXFCaiZG.PRISMA-extracapsular dissection versus superficial parotidectomy in treatment of benign parotid tumors: evidence from 3194 patients.Medicine2015;
94:e1237
3.
WittRLRejtoL.Pleomorphic adenoma: extracapsular dissection versus partial superficial parotidectomy with facial nerve dissection. Del Med J2009;
81:119–25
4.
NøhrAAndreasenSTherkildsenMHHomøeP.Stationary facial nerve paresis after surgery for recurrent parotid pleomorphic adenoma: a follow-up study of 219 cases in Denmark in the period 1985-2012. Eur Arch Otorhinolaryngol2016;
273:3313–9
5.
RégloixSBGrinholtz-HaddadJMaurinOGenestierLLisanQPonsY.Facial nerve monitoring during parotidectomy: a two-center retrospective study. Iran J Otorhinolaryngol2016;
28:255–60
6.
BaekkevoldESRoussigneMYamanakaTJohansenFEJahnsenFLAmalricFBrandtzaegPErardMHaraldsenGGirardJP.Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol2003;
163:69–79
7.
SchmitzJOwyangAOldhamESongYMurphyEMcClanahanTKZurawskiGMoshrefiMQinJLiXGormanDMBazanJFKasteleinRA. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines.Immunity2005;
23:479–90
8.
BarksbyHELeaSRPreshawPMTaylorJJ.The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin Exp Immunol2007;
149:217–25
9.
MoussionCOrtegaNGirardJP.The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'?PLoS One2008;
3:e3331
10.
DivekarRKitaH.Recent advances in epithelium-derived cytokines (IL-33, IL-25, and thymic stromal lymphopoietin) and allergic inflammation. Curr Opin Allergy Clin Immunol2015;
15:98–103
11.
RiderPVoronovEDinarelloCAApteRNCohenI.Alarmins: feel the stress. J Immunol2017;
198:1395–402
12.
MuellerTJaffeAS.Soluble ST2-analytical considerations. Am J Cardiol2015;
115:8B–21B
13.
KakkarRLeeRT.The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov2008;
7:827–40
14.
WeinbergEOShimpoMDe KeulenaerGWMacGillivrayCTominagaSSolomonSDRouleauJLLeeRT.Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation2002;
106:2961–6
15.
SabatineMSMorrowDAHigginsLJMacGillivrayCGuoWBodeCRifaiNCannonCPGersztenRELeeRT.Complementary roles for biomarkers of biomechanical strain, ST2 and NT-proBNP, in patients with ST-elevation myocardial infarction. Circulation2008;
117:1936–44
16.
BergisDKassisVRanglackAKoeberleVPiiperAKronenbergerBZeuzemSWaidmannORadekeHH.High serum levels of the interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma. Transl Oncol2013;311–8
17.
AkimotoMMaruyamaRTakamaruHOchiyaTTakenagaK.Soluble IL-33 receptor sST2 inhibits colorectal cancer malignant growth by modifying the tumour microenvironment. Nat Comms2016;
7:13589
18.
KimJYLimSCKimGYunHJAhnSGChoiHS.Interleukin-33/ST2 axis promotes epithelial cell transformation and breast tumorigenesis via upregulation of COT activity. Oncogene2015;
34:4928–38
19.
AkimotoMHayashiJINakaeSSaitoHTakenagaK.Interleukin-33 enhances programmed oncosis of ST2L-positive low-metastatic cells in the tumour microenvironment of lung cancer. Cell Death Dis2016;
7:e2057
20.
YuXXHuZShenXDongLYZhouWZHuWH.IL-33 promotes gastric cancer cell invasion and migration via ST2-ERK1/2 pathway. Dig Dis Sci2015;
60:1265–72
21.
ZhangPLiuXKChuZYeJCLiKLZhuangWLYangDJJiangYF.Detection of interleukin-33 in serum and carcinoma tissue from patients with hepatocellular carcinoma and its clinical implications. J Int Med Res2012;
40:1654–61
22.
ChenSFNiehSJaoSWWuMZLiuCLChangYCLinYS.The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma. J Pathol2013;
231:180–9
23.
WasmerMHKrebsP.The role of IL-33-dependent inflammation in the tumor microenvironment. Front Immunol2017;
7:682
24.
JungSMLeeJBaekSYLeeJHLeeJParkKSParkSHKimHYKwokSK.The Interleukin 33/ST2 axis in patients with primary Sjögren syndrome: expression in serum and salivary glands, and the clinical association. J Rheumatol2015;
42:264–71
25.
RössleMCathomasGBonapaceLSachsMDehlerSStorzMHuberGMochHJuntTMertzKD.Interleukin-33 expression indicates a favorable prognosis in malignant salivary gland tumors. Int J Surg Pathol2016;
24:394–400
26.
De la FuenteMMacDonaldTTHermosoMA.The IL-33/ST2 axis: role in health and disease. Cytokine Growth Factor Rev2015;
26:615–23
27.
HaghshenasMRKhademiBAshrafMJGhaderiAErfaniN.Helper and cytotoxic T-cell subsets (Th1, Th2, Tc1, and Tc2) in benign and malignant salivary gland tumors. Oral Dis2016;
22:566–72
28.
XuJGuardadoJHoffmanRXuHNamasRVodovotzYXuLRamadanMBrownJTurnquistHRBilliarTR.IL33-mediated ILC2 activation and neutrophil IL5 production in the lung response after severe trauma: a reverse translation study from a human cohort to a mouse trauma model. PLoS Med2017;
25:e1002365
29.
ZhangHFWuMXLinYQXieSLHuangTCLiuPMNieRQMengQQLuoNSChenYXWangJF.IL-33 promotes IL-10 production in macrophages: a role for IL-33 in macrophage foam cell formation. Exp Mol Med2017;
3:e388
30.
MartinezEFNapimogaMHMontalliVAde AraújoNSde AraújoVC.In vitro cytokine expression in in situ-like areas of malignant neoplasia. Arch Oral Biol2013;
58:552–7
TodaroMZerilliMRicci-VitianiLBiniMPerez AleaMMaria FlorenaAMiceliLCondorelliGBonventreSDi GesùGDe MariaRStassiG.Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells. Cancer Res2006;
66:1491–9
33.
SuzukiALelandPJoshiBHPuriRK.Targeting of IL-4 and IL-13 receptors for cancer therapy. Cytokine2015;
75:79–88
34.
FurukawaSMoriyamaMMiyakeKNakashimaHTanakaAMaeharaTIizuka-KogaMTsuboiHHayashidaJNIshiguroNYamauchiMSumidaTNakamuraS.Interleukin-33 produced by M2 macrophages and other immune cells contributes to Th2 immune reaction of IgG4-related disease. Sci Rep2017;
7:42413
35.
QuerMGuntinas-LichiusOMarchalFVander PoortenVChevalierDLeónXEiseleDDulguerovP.Classification of parotidectomies: a proposal of the European Salivary Gland Society. Eur Arch Otorhinolaryngol2016;
273:3307–12
36.
EdaSKaufmannJRoosWPohlS.Development of a new microparticle-enhanced turbidimetric assay for C-reactive protein with superior features in analytical sensitivity and dynamic range. J Clin Lab Anal1998;
12:137–44
37.
de SiqueiraECde SouzaFTAGomezRSGomesCCde SouzaRP.Does cell phone use increase the chances of parotid gland tumor development? A systematic review and meta-analysis. J Oral Pathol Med2017;
46:480–3
38.
de SouzaFTCorreia-SilvaJFFerreiraEFSiqueiraECDuarteAPGomezMVGomezRSGomesCC.Cell phone use and parotid salivary gland alterations: no molecular evidence. Cancer Epidemiol Biomarkers Prev2014;
23:1428–31
39.
RozmilowskaIMAdamczyk-SowaM.What is the role of interleukin 33 and ST2 receptor in myasthenia gravis?J Neuroimmunol2018;
315:50–7
40.
HuHSunJWangCBuXLiuXMaoYWangH.IL-33 facilitates endocrine resistance of breast cancer by inducing cancer stem cell properties. Biochem Biophys Res Commun2017;
8:643–50
41.
YangZPLingDYXieYHWuWXLiJRJiangJZhengJLFanYHZhangY.The association of serum IL-33 and sST2 with breast cancer. Dis Markers2015;
2015:516895
42.
SchindlerCDarnellJEJr.
Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem1995;
64:621–51
43.
de AraújoVCFuruseCCuryPRAltemaniAde AraújoNS.STAT3 expression in salivary gland tumours. Oral Oncol2008;
44:439–45
44.
AndreasenSTherkildsenMHGrauslundMFriis-HansenLWesselIHomøeP.Activation of the interleukin-6/Janus kinase/STAT3 pathway in pleomorphic adenoma of the parotid gland. APMIS2015;
123:706–15
45.
TheoharidesTCPetraAITaracanovaAPanagiotidouSContiP.Targeting IL-33 in autoimmunity and inflammation. J Pharmacol Exp Ther2015;
354:24–31
46.
YuYDengWLeiJ.Interleukin-33 promotes Th2 immune responses in infected mice with Schistosoma japonicum. Parasitol Res2015;
114:2911–8
47.
BarnesLEvesonJWReichartPSidranskyD (eds). Pathology and genetics of head and neck tumours (IARC/World Health Organization classification of tumours).
Lyon, France:
IARC Press, 2005
48.
MichalMSkalovaASimpsonRHLeivoIRyskaAStarekI.Well-differentiated acinic cell carcinoma of salivary glands associated with lymphoid stroma. Hum Pathol1997;
28:595–600
49.
ChinKWBillingsKRIshiyamaAWangMBWackymPA.Characterization of lymphocyte subpopulations in Warthin’s tumor. Laryngoscope1995;
105:928–33
50.
KuzenkoYVRomanukAMDyachenkoOOHudymenkoO.Pathogenesis of Warthin's tumors. Interv Med Appl Sci2016;
8:41–18
51.
Pascual-FigalDJanuzziJLJr.
The biology of ST2: the international ST2 consensus panel. Am J Cardiol2015;
115(7Suppl):3B–7B
52.
TrajkovicVSweetMJXuD.T1/ST2 – an IL-1 receptor-like modulator of immune responses. Cytokine Growth Factor Rev2004;
15:87–95
53.
BalkwillFMantovaniA.Inflammation and cancer: back to Virchow?Lancet2001;
357:539–45
54.
SowaPMisiolekMPasinskiBBartoszGSoszynskiMAdamczyk-SowaMSadowska-BartoszI.Oxidative stress markers in patients with parotid gland tumors. A pilot study. Biomed Res Int2018;
2018:7
55.
MantsopoulosKPsychogiosGAgaimyAKünzelJZenkJIroHBohrC.Inflamed benign tumors of the parotid gland: diagnostic pitfalls from a potentially misleading entity. Head Neck2015;
37:23–9
56.
BundgaardNEriksenHEGreisenO.Inflamed adenolymphoma with cholesterol granuloma. J Laryngol Otol1987;
101:967–70
57.
SowaPMisiolekMOreckaBCzeciorEAdamczyk-SowaM.Serum levels of selected adipocytokines in benign and malignant parotid gland tumor patients. Cytokine2018;
106:40–4
58.
SeverinoVOBeghiniMde AraújoMFde MeloMLRMiguelCBRodriguesWFde Lima PereiraSA.Expression of IL-6, IL-10, IL-17 and IL-33 in the peri-implant cervicular fluid of patients with peri-implant mucositis and peri-implantitis. Arch Oral Biol2016;
72:194–9
59.
ThierryAGiraudSRobinABarraABridouxFAmeteauVHauetTGirardJPTouchardGGombertJMHerbelinA.The alarmin concept applied to human renal transplantation: evidence for a differential implication of HMGB1 and IL-33. PLoS One2014;
20:e88742
60.
GümüşPNizamNNalbantsoyAÖzçakaÖBuduneliN.Saliva, serum levels of interleukin-21, -33 and prostaglandin E2 in patients with generalised aggressive or chronic periodontitis. Oral Health Prev Dent2017;
15:385–90
